Adjutec further attended the joint meeting of European Society of Clinical Microbiology and Infectious Disease (ESCMID) and American Society for Microbiology (ASC) in Dublin 3-7th October. Major topics included preclinical pipelines and clinical trials designs of antibiotic products. These presentations were highly relevant to APC148 and APC247 stage of development.
Adjutec participated also in several meetings with existing and potential R&D suppliers and funding bodies to explore plan further R&D activities.
“These meetings are important for scientific updates and face-face interactions with our network of R&D collaborators. "Adjutec depends on finding the best suppliers for outsourcing R&D activities and spend a lot of efforts in securing high quality collaborators”- comments CEO Bjørn Klem.
About antimicrobial resistance (AMR) – https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
AMR is a global health threat that kills 1.27mill people every year. It requires urgent multi-sectoral action in order to achieve the Sustainable Development Goals (SDGs). WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials is the main drivers in the development of drug-resistant pathogens. Lack of clean water, sanitation and inadequate infection prevention and control promote the spread of microbes, some of which can be resistant to antimicrobial treatment. The cost of AMR to the economy is significant. In addition to death and disability, prolonged illness results in longer hospital stays at intensive care units and isolate wards. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.
About AdjuTec Pharma
AdjuTec Pharma is a Company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The Company technology offers a unique mechanism of action that inactivates bacterial defense enzymes and restores bacterial sensitivity to antibiotics. The Company lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at Department of Pharmacy, University of Oslo. The Company is located at Rebel, Universitetsgata 2 - downtown Oslo.
For more information, please visit www.adjutecpharma.com
Please contact: info@adjutecpharma.com